Literature DB >> 21094901

Incretin hormone secretion over the day.

Bo Ahrén1, Richard D Carr, Carolyn F Deacon.   

Abstract

The two incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are key factors in the regulation of islet function and glucose metabolism, and incretin-based therapy for type 2 diabetes has gained considerable interest during recent years. Regulation of incretin hormone secretion is less well characterized. The main stimulus for incretin hormone secretion is presence of nutrients in the intestinal lumen, and carbohydrate, fat as well as protein all have the capacity to stimulate GIP and GLP-1 secretion. More recently, it has been established that a diurnal regulation exists with incretin hormone secretion to an identical meal being greater when the meal is served in the morning compared to in the afternoon. Finally, whether incretin hormone secretion is altered in disease states is an area with, so far, controversial results in different studies, although some studies have demonstrated reduced incretin hormone secretion in type 2 diabetes. This review summarizes our knowledge on regulation of incretin hormone secretion and its potential changes in disease states.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21094901     DOI: 10.1016/B978-0-12-381517-0.00007-2

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  9 in total

Review 1.  Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.

Authors:  Bo Ahrén
Journal:  World J Diabetes       Date:  2014-02-15

Review 2.  Physiology of incretins in health and disease.

Authors:  Carolyn F Deacon; Bo Ahrén
Journal:  Rev Diabet Stud       Date:  2011-11-10

3.  Consequences on islet and incretin hormone responses to dinner by omission of lunch in healthy men.

Authors:  Ola Lindgren; Bo Ahrén
Journal:  Endocrinol Diabetes Metab       Date:  2020-04-28

4.  GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat.

Authors:  Lena Ohlsson; Alison B Kohan; Patrick Tso; Bo Ahrén
Journal:  Regul Pept       Date:  2014-02-28

5.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

6.  Incretin receptor null mice reveal key role of GLP-1 but not GIP in pancreatic beta cell adaptation to pregnancy.

Authors:  R Charlotte Moffett; Srividya Vasu; Bernard Thorens; Daniel J Drucker; Peter R Flatt
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

7.  Elevated circulating fasting glucagon-like peptide-1 in surgical patients with aortic valve disease and diabetes.

Authors:  Camilla Krizhanovskii; Stelia Ntika; Christian Olsson; Per Eriksson; Anders Franco-Cereceda
Journal:  Diabetol Metab Syndr       Date:  2017-10-10       Impact factor: 3.320

Review 8.  Time-limited diets and the gut microbiota in cardiometabolic disease.

Authors:  Karina Ratiner; Hagit Shapiro; Kim Goldenberg; Eran Elinav
Journal:  J Diabetes       Date:  2022-06-13       Impact factor: 4.530

9.  Effects of substituting eggs for high-carbohydrate breakfast foods on the cardiometabolic risk-factor profile in adults at risk for type 2 diabetes mellitus.

Authors:  Kevin C Maki; Orsolya M Palacios; Melvyn W Kramer; Rupal Trivedi; Mary R Dicklin; Meredith L Wilcox; Cathleen E Maki
Journal:  Eur J Clin Nutr       Date:  2020-03-09       Impact factor: 4.016

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.